Neumora Therapeutics (NMRA)

• Market cap: $1.75B
• 1 day: 3.33%
• 5 days: 4.33%
• 1 month: 10.83%
• 3 months: -16.02%
• 6 months: 22.60%
• Year to date: -35.80%
• 1 year: -25.07%
• 5 years: -33.23%
• 10 years: -33.23%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Employees: 109

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

55% more call options, than puts

Call options by funds: $14.6M | Put options by funds: $9.43M

48% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 23

27% more capital invested

Capital invested by funds: $714M [Q2] → $906M (+$192M) [Q3]

11% more funds holding

Funds holding: 93 [Q2] → 103 (+10) [Q3]

2.67% less ownership

Funds ownership: 45.51% [Q2] → 42.85% (-2.67%) [Q3]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q2] → 4 (-1) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 38% upside
• Avg. target: $24 124% upside
• High target: $30 176% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 43% 1-year accuracy 71 / 167 met price target	177% upside $30	Buy Reiterated	16 Dec 2024
RBC Capital Brian Abrahams 19% 1-year accuracy 15 / 79 met price target	167% upside $29	Outperform Reiterated	22 Nov 2024
Needham Ami Fadia 37% 1-year accuracy 57 / 154 met price target	112% upside $23	Buy Reiterated	13 Nov 2024
JP Morgan Tessa Romero 22% 1-year accuracy 4 / 18 met price target	38% upside $15	Neutral Downgraded	5 Nov 2024